Skip to main content

CASE REPORT article

Front. Psychiatry
Sec. Neuroimaging
Volume 15 - 2024 | doi: 10.3389/fpsyt.2024.1450800
This article is part of the Research Topic Rising Stars in Psychiatry: 2024 View all 10 articles

An ARFID case report assessment with 18F-FDG PET/MRI and treatment with olanzapine, escitalopram and fluoxetine in adult

Provisionally accepted
Meichen Liu Meichen Liu 1Yiheng Chang Yiheng Chang 1Xueting Xie Xueting Xie 1Yudan Liu Yudan Liu 1Tian Shiyun Tian Shiyun 2Chun Yang Chun Yang 2Ziqi Zhao Ziqi Zhao 3*Huimin Zhang Huimin Zhang 1*
  • 1 Department of Neurology, First Affiliated Hospital, Dalian Medical University, Dalian, China
  • 2 Department of Radiology, First Affiliated Hospital, Dalian Medical University, Dalian, Liaoning Province, China
  • 3 Department of General Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, China

The final, formatted version of the article will be published soon.

    Background: Avoidant/restrictive food intake disorder (ARFID), a DSM-5-introduced eating disorder, is increasingly prevalent and challenging to treat, primarily affecting children and adolescents, with limited adult case reports. This rarity in adults leads to misdiagnosis or underdiagnosis, and treatment experiences are scarce.Case presentation: This report details an adult ARFID case, where the patient's fear of food intake followed gastric damage from corn ingestion, resulting in a restrictive diet of rice porridge due to gastric pain. The behavior is driven by fear of eating-related adverse effects.Result: Based on clinical symptoms assessment, semi-structured interviews, and comprehensive testing, including PET/MRI scans to exclude secondary conditions, a diagnosis of ARFID was confirmed. ARFID, a newly introduced diagnosis in the DSM-5, is uncommon in adults with sparse case data. Differentiating it from gastrointestinal diseases and other psychiatric conditions is crucial for precise diagnosis and focused treatment.In this paper, we report the clinical diagnosis, imaging manifestations, treatment, and follow-up of an adult ARFID case, highlighting the utility of neuroimaging in diagnosis and differentiation. It also assesses the therapeutic efficacy of olanzapine, escitalopram oxalate, and fluoxetine hydrobromide, offering clinical guidance for diagnosing and managing ARFID.

    Keywords: Avoidant/restrictive food intake disorder, Magnetic Resonance Imaging, Positronemission tomography, olanzapine, escitalopram, Fluoxetine, Neuroimaging, case report

    Received: 18 Jun 2024; Accepted: 19 Dec 2024.

    Copyright: © 2024 Liu, Chang, Xie, Liu, Shiyun, Yang, Zhao and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Ziqi Zhao, Department of General Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, China
    Huimin Zhang, Department of Neurology, First Affiliated Hospital, Dalian Medical University, Dalian, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.